WO2000042216A3 - Predisposition genetique - Google Patents

Predisposition genetique Download PDF

Info

Publication number
WO2000042216A3
WO2000042216A3 PCT/EP2000/000319 EP0000319W WO0042216A3 WO 2000042216 A3 WO2000042216 A3 WO 2000042216A3 EP 0000319 W EP0000319 W EP 0000319W WO 0042216 A3 WO0042216 A3 WO 0042216A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene
genetic predisposition
abnormal calcification
calcification conditions
conditions
Prior art date
Application number
PCT/EP2000/000319
Other languages
English (en)
Other versions
WO2000042216A2 (fr
Inventor
Philip Kusk
Original Assignee
Osteometer Biotech As
Philip Kusk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9901037.3A external-priority patent/GB9901037D0/en
Priority claimed from GBGB9912585.8A external-priority patent/GB9912585D0/en
Application filed by Osteometer Biotech As, Philip Kusk filed Critical Osteometer Biotech As
Priority to EP00909076A priority Critical patent/EP1144686A2/fr
Priority to AU31492/00A priority patent/AU3149200A/en
Priority to JP2000593773A priority patent/JP2005517379A/ja
Publication of WO2000042216A2 publication Critical patent/WO2000042216A2/fr
Publication of WO2000042216A3 publication Critical patent/WO2000042216A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Cette invention concerne des procédés permettant d'établir la prédisposition d'un individu à des conditions de calcification anormales, telle que l'ostéoporose, lesquels procédés consistent à déterminer le génotype d'un promoteur pour le gène de sialoprotéine des os, pour le gène de protéine gla matricielle, pour le gène d'ostéopontine ou pour le gène d'ostéoprotégérine, que se soit de manière individuelle ou combinée. Cette invention concerne également des variations alléliques spécifiques pour chaque promoteur.
PCT/EP2000/000319 1999-01-18 2000-01-17 Predisposition genetique WO2000042216A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00909076A EP1144686A2 (fr) 1999-01-18 2000-01-17 Predisposition genetique
AU31492/00A AU3149200A (en) 1999-01-18 2000-01-17 Genetic predisposition
JP2000593773A JP2005517379A (ja) 1999-01-18 2000-01-17 遺伝的疾病素因

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9901037.3A GB9901037D0 (en) 1999-01-18 1999-01-18 Genetic predisposition
GB9901037.3 1999-01-18
GB9912585.8 1999-05-28
GBGB9912585.8A GB9912585D0 (en) 1999-05-28 1999-05-28 Genetic predisposition

Publications (2)

Publication Number Publication Date
WO2000042216A2 WO2000042216A2 (fr) 2000-07-20
WO2000042216A3 true WO2000042216A3 (fr) 2000-11-02

Family

ID=26314996

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/000319 WO2000042216A2 (fr) 1999-01-18 2000-01-17 Predisposition genetique

Country Status (4)

Country Link
EP (1) EP1144686A2 (fr)
JP (1) JP2005517379A (fr)
AU (1) AU3149200A (fr)
WO (1) WO2000042216A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7720600A (en) * 1999-09-27 2001-04-30 Eli Lilly And Company Osteoprotegerin regulatory region
CA2682114C (fr) 2007-03-30 2017-08-01 Chu Sainte Justine Procede de determination d'un risque de scoliose

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0705842A2 (fr) * 1994-10-06 1996-04-10 Hoechst Aktiengesellschaft Régulation des gènes par stimulation du chondrocytes avec 1L-1bêta
WO1997003555A1 (fr) * 1995-07-17 1997-02-06 Hoechst Pharmaceuticals & Chemicals K.K. Modele animal transgenique d'osteopenie
EP0784093A1 (fr) * 1995-12-22 1997-07-16 Amgen Inc. Ostéoprotégerin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0705842A2 (fr) * 1994-10-06 1996-04-10 Hoechst Aktiengesellschaft Régulation des gènes par stimulation du chondrocytes avec 1L-1bêta
WO1997003555A1 (fr) * 1995-07-17 1997-02-06 Hoechst Pharmaceuticals & Chemicals K.K. Modele animal transgenique d'osteopenie
EP0784093A1 (fr) * 1995-12-22 1997-07-16 Amgen Inc. Ostéoprotégerin

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BRANDSTROM, H. (1) ET AL: "Polymorphism in the promoter region of the human gene for osteoprotegerin: Correlation with bone mineral density.", JOURNAL OF BONE AND MINERAL RESEARCH, (SEPT., 1999) VOL. 14, NO. SUPPL. 1 PP. S334. MEETING INFO.: TWENTY-FIRST ANNUAL MEETING OF THE AMERICAN SOCIETY FOR BONE AND MINERAL RESEARCH ST. LOUIS, MISSOURI, USA SEPTEMBER 30-OCTOBER 4 1999 AMERICAN SOCIETY, XP000915449 *
BUCAY N ET AL: "osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification", GENES AND DEVELOPMENT,US,COLD SPRING HARBOR LABORATORY PRESS, NEW YORK, vol. 12, no. 9, 1 May 1998 (1998-05-01), pages 1260 - 1268, XP002090118, ISSN: 0890-9369 *
KIM R H ET AL: "Identification of a vitamin D3-response element that overlaps a unique inverted TATA box in the rat bone sialoprotein gene.", BIOCHEMICAL JOURNAL, (1996 AUG 15) 318 ( PT 1) 219-26., XP002142619 *
LUO: "Spontaneous calcification of arteries and cartilage in mice lacking GLA protein", NATURE, vol. 386, 6 March 1996 (1996-03-06), pages 78 - 81, XP002142620 *
MUNROE P B ET AL: "Mutations in the gene encoding the human matrix Gla protein cause Keutel syndrome.", NATURE GENETICS, (1999 JAN) 21 (1) 142-4., XP000929109 *

Also Published As

Publication number Publication date
JP2005517379A (ja) 2005-06-16
EP1144686A2 (fr) 2001-10-17
AU3149200A (en) 2000-08-01
WO2000042216A2 (fr) 2000-07-20

Similar Documents

Publication Publication Date Title
WO2002018638A3 (fr) Detection de polymorphismes dans cyp2d6
WO2006099259A3 (fr) Nouvelles mutations faux-sens et polymorphismes a simple nucleotide dans le gene du type rabphillin-3a et utilisations correspondantes
WO2003087763A3 (fr) Association de polymorphismes dans la region du gene sost avec la densite minerale de l'os
AU2299999A (en) Dnas or genes participating in parkinson's disease
WO2002086156A3 (fr) Nouveaux polynucleotides et nouveaux polypeptides du gene ifn$g(a)-17
WO2000022122A3 (fr) Genes, proteines et marqueurs bialleliques lies a une maladie du systeme nerveux central
WO2000042216A3 (fr) Predisposition genetique
WO2002095067A3 (fr) Nouveaux polynucleotides et polypeptides du gene ifnα-14
WO2001023410A3 (fr) Isogenes cibles a usage medicamenteux: polymorphismes dans le gene d'interleukine
WO2000058510A3 (fr) Genes, proteines, et marqueurs bialleliques associes a la schizophrenie
WO1997043446A3 (fr) Methode et appareil permettant de diagnostiquer une predisposition a certaines affections, notamment l'osteoporose, sur la base du polymorphisme d'un gene de l'il-6
WO2003000896A3 (fr) Nouveaux polynucleotides et polypeptides du gene ifn$g(a)-5
WO2002101048A3 (fr) Nouveaux polynucleotides et polypeptides du gene ifn$g(a)-7
AU6091199A (en) Method for determining susceptibility to heart disease by screening polymorphisms in the vitamin d receptor gene
WO2004090164A3 (fr) Procede permettant de determiner la sante ecologique ou agricole d'un sol
WO2003079747A3 (fr) Polynucleotide isole associe au diabete sucre de type ii et procedes d'utilisation associes
AU2000263446A1 (en) Drug target isogenes: polymorphisms in the interleukin 4 receptor alpha gene
WO2003018835A3 (fr) Procede de detection rapide d'haplotypes
AU6091099A (en) Method for determining susceptibility to bone damage by screening polymorphisms in the vitamin d receptor gene
WO2001077380A3 (fr) Sequences
WO2001058914A3 (fr) Haplotypes du gene de l'interleukine 15
WO2001011010A3 (fr) Isogenes cibles de medicaments : polymorphismes dans le gene de la sous-unite alpha du recepteur i de l'immunoglobuline e
EP0854186A3 (fr) Gène de division cellulaire DivIB de Staphylococcus aureus
WO2002083733A3 (fr) Nouveaux polynucleotides et polypeptides du gene ifn$g(a)-6
WO2001027312A3 (fr) Isogenes cibles pour medicaments: polymorphismes dans le gene recepteur de l'acetylcholine muscarinique m1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 593773

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000909076

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000909076

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09889491

Country of ref document: US

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWW Wipo information: withdrawn in national office

Ref document number: 2000909076

Country of ref document: EP